Phase 1 Systemic Lupus Erythematosus trials recruiting now

All Systemic Lupus Erythematosus trials, every phase

Other phases for Systemic Lupus Erythematosus

Phase 1 Systemic Lupus Erythematosus trials

• A Clinical Study of CD19 CAR-T in Active Systemic Lupus Erythematosus
  NCT06106906 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• A Clinical Study of CD19 Universal CAR-γδT Cells in Active Systemic Lupus Erythematosus
  NCT06106893 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004)
  NCT07363590 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 21 locations
• A Phase 1b Study of Budoprutug in Systemic Lupus Erythematosus (SLE)
  NCT07011043 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 18 locations
• A Study of GNC-038 Tetra-specific Antibody Injection in Patients With Systemic Lupus Erythematosus
  NCT06857214 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese, and Japanese Participants and CTD-ILD Participants
  NCT06576271 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 28 locations
• A Study of GSK5926371 in Participants With B-cell Driven Autoimmune Rheumatic Diseases (ARD)
  NCT07371468 · Phase: Phase 1 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 19 locations
• A Study of IMC-002 for the Treatment of Active Systemic Lupus Erythematosus
  NCT06535412 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• A Study of Intravenous CPTX2309 in Healthy Participants and Participants With Moderate to Severe Rheumatoid Arthritis (RA) or Systemic Lupus Erythematosus (SLE)
  NCT06917742 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 3 locations
• A Study of LY4298445 in Healthy Participants and Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)
  NCT07276958 · Phase: Phase 1 · Ages: 18 Years to 55 Years · Sex: All (male and female) · 9 locations
• A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions and Subcutaneous Injections of ABBV-519 in Adult Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)
  NCT07607964 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 10 locations
• A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants With Systemic Lupus Erythematosus (SLE), Sjogren's Disease (SjD) and Rheumatoid Arthritis (RA)
  NCT06977724 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 11 locations
• A Study to Assess the Safety and PK/PD of LBL-047 in Healthy Adults and Patients With Systemic Lupus Erythematosus
  NCT07323173 · Phase: Phase 1 · Ages: 18 Years to 60 Years · Sex: All (male and female) · 12 locations
• A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.
  NCT06916806 · Phase: Phase 1 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 37 locations
• Alnuctamab for Refractory SLE (LATTE Study)
  NCT07219563 · Phase: Phase 1 · Ages: 18 Years to 60 Years · Sex: All (male and female) · 1 location
• An Exploratory Clinical Study of YTS109 Cell for R/R Autoimmune Diseases
  NCT07236762 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• BAFF CAR-T Cells (LMY-920) for Systemic Lupus Erythematosus
  NCT06340750 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• CAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapse/Refractory Autoimmune Diseases
  NCT06941129 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• CAR-T Cells in Systemic B Cell Mediated Autoimmune Disease
  NCT06347718 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• CD19/BCMA CAR-T Cell Therapy for Refractory/Moderate-to-severe Systemic Lupus Erythematosus
  NCT06349343 · Phase: Phase 1 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• Clinical Study of A-319 in the Treatment of Active/Refractory Systemic Lupus Erythematosus
  NCT06400537 · Phase: Phase 1 · Ages: 18 Years to 60 Years · Sex: All (male and female) · 2 locations
• Efficacy and Safety of CD19 UCAR T Cells in Refractory Systemic Lupus Erythematosus
  NCT06691152 · Phase: Phase 1 · Ages: 5 Years and older · Sex: All (male and female) · 1 location
• Efficacy and Safety of HN2301 in Autoimmune Diseases（AIDs）
  NCT06801119 · Phase: Phase 1 · Ages: 18 Years to 69 Years · Sex: All (male and female) · 1 location
• Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE)
  NCT06350110 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 90 Years · Sex: All (male and female) · 1 location
• Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases.
  NCT06581562 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders
  NCT06434363 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• REACT-01: Reversing Autoimmunity Through Cell Therapy
  NCT06465147 · Phase: Phase 1 · Ages: 2 Years to 30 Years · Sex: All (male and female) · 1 location
• RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
  NCT06121297 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 23 locations
• Safety, Tolerability, and Pharmacokinetics of Single Doses of HC022 in Healthy Subjects.
  NCT06657703 · Phase: Phase 1 · Ages: 18 Years to 55 Years · Sex: All (male and female) · 3 locations
• Sequential CAR-T Cells Targeting BCMA/CD19 in Patients With Relapsed/ Refractory Autoimmune Diseases
  NCT06428188 · Phase: Phase 1, Phase 2 · Ages: 21 Years to 90 Years · Sex: All (male and female) · 1 location
• Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants
  NCT07201558 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 34 locations
• Study of BCMA/CD70 CAR-T Therapy for Refractory cSLE
  NCT06934447 · Phase: Phase 1 · Ages: 5 Years and older · Sex: All (male and female) · 1 location
• Study of CD19 CAR-T Therapy for Refractory SLE
  NCT07403097 · Phase: Phase 1 · Ages: 5 Years and older · Sex: All (male and female) · 1 location
• Study of Ultra-Fast BCMA/CD70 CAR-T Therapy for Refractory SLE
  NCT07318259 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Study of Ultra-Fast CD19 CAR-T Therapy for Refractory SLE
  NCT07331467 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Study of Ultra-Fast CD19 CAR-T Therapy for Refractory SLE
  NCT07233642 · Phase: Phase 1 · Ages: 5 Years and older · Sex: All (male and female) · 1 location
• Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
  NCT03816345 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 260 locations
• Treatment and Clinical Outcomes Among SLE Patients in Pregnancy
  NCT04976465 · Phase: Phase 1 · Ages: 20 Years to 45 Years · Sex: Female · 1 location
• UB-VV410 in Subjects With Active Refractory Systemic Lupus Erythematosus or Lupus Nephritis
  NCT07109986 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• UC-MSC Cell Therapy Study for Systemic Lupus Erythematosus (SLE) Patients
  NCT06737380 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• US Zamto-cel Autoimmune Diseases
  NCT06708845 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location

Common questions

What does Phase 1 mean?

See how clinical trials work.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.